Payment overview · 2025
General Payments
$229.31
11 reported records · 7 companies
Healthcare provider profile · identity verified
Michael Gary Martin, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · MEMPHIS, TN · NPI 1588671085
Verified facts
What the public records show
CMS Open Payments records show Michael Gary Martin, MD received $229.31 in general payments during 2025 across 11 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Erleada, Keytruda, Xtandi.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRYCEL as an associated drug or biological on 32 records involving 32 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Sprycel by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Erleada by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Xarelto by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEYTRUDA as an associated drug or biological on 46588 records involving 15767 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Keytruda by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ibrance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $50.93 | 22.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.82 | 20.9% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $39.26 | 17.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.50 | 12.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.86 | 10.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.54 | 10.3% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.40 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.31 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $50.93 | 3 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $47.82 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $47.82 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ERLEADA erleada |
2025 | Erleada | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEYTRUDA keytruda |
2025 | Keytruda | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | SPRYCEL open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 32 recipient NPIs · example record 1184390211 |
Sprycel · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | KEYTRUDA open payments reported associated product |
CMS Open Payments — General Payments 46588 supporting records · 15767 recipient NPIs · example record 1237992210 |
Keytruda · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 87 | 18 |
| Prednisone | Prednisone | 69 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 18 |
| Acyclovir | Acyclovir | 58 | 12 |
| Xarelto | Rivaroxaban | 45 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 16 |
| Anastrozole | Anastrozole | 42 | 15 |
| Sprycel | Dasatinib | 42 | suppressed |
| Letrozole | Letrozole | 41 | 11 |
| Brukinsa | Zanubrutinib | 40 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 39 | 24 |
| Azithromycin | Azithromycin | 37 | suppressed |
| Dexamethasone | Dexamethasone | 36 | 12 |
| Imbruvica | Ibrutinib | 32 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | suppressed |
| Exemestane | Exemestane | 28 | suppressed |
| Gabapentin | Gabapentin | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Entecavir | Entecavir | 25 | suppressed |
| Revlimid | Lenalidomide | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 12 |
| Keytruda | Pembrolizumab | 22 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | suppressed |
| Hydroxyurea | Hydroxyurea | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Ibrance | Palbociclib | 18 | suppressed |
| Erleada | Apalutamide | 17 | suppressed |
| Xtandi | Enzalutamide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Eligard | Leuprolide Acetate | 15 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Mvasi | Bevacizumab-Awwb | 14 | suppressed |
| Truxima | Rituximab-Abbs | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 13 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 13 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 12 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Lupron Depot | Leuprolide Acetate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Cabometyx | Cabozantinib S-Malate | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.31 · 11 records | E.R. Squibb & Sons, L.L.C. | AKEEGA, BALVERSA, DARZALEX, ERLEADA, JAYPIRCA, JEMPERLI, KEYTRUDA, OPDIVO, ORGOVYX, TALZENNA, TECVAYLI, VERZENIO, XTANDI, ZEJULA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Erleada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error